Recession-Proof Riches: 3 Stocks That Thrive in Any Economy

InvestorPlace04-19

These companies have the fundamental ability to capitalize on market leads and derive constant growth despite economic fluctuations. Starbucks (SBUX): The company recorded a solid increase in U.S. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428119435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-19 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428119435","market":"us","top_or_hot":-1,"title":"Recession-Proof Riches: 3 Stocks That Thrive in Any Economy","media":"InvestorPlace","content":"<div>\n<p>These companies have the fundamental ability to capitalize on market leads and derive constant growth despite economic fluctuations.\nStarbucks (SBUX): The company recorded a solid increase in U.S. ...</p>\n\n<a href=\"https://investorplace.com/2024/04/recession-proof-riches-3-stocks-that-thrive-in-any-economy/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recession-Proof Riches: 3 Stocks That Thrive in Any Economy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecession-Proof Riches: 3 Stocks That Thrive in Any Economy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 00:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/04/recession-proof-riches-3-stocks-that-thrive-in-any-economy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These companies have the fundamental ability to capitalize on market leads and derive constant growth despite economic fluctuations.\nStarbucks (SBUX): The company recorded a solid increase in U.S. ...</p>\n\n<a href=\"https://investorplace.com/2024/04/recession-proof-riches-3-stocks-that-thrive-in-any-economy/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"https://investorplace.com/2024/04/recession-proof-riches-3-stocks-that-thrive-in-any-economy/","article_id":"2428119435","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428119435","pubTimestamp":1713456491,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","THAC":"Thrive Acquisition Corp","SBUX":"星巴克","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","JNJ":"强生","LU0823411888.USD":"法巴消费创新基金 Cap","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","AMAM":"Ambrx Biopharma Inc","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","PACI.U":"PROOF Acquisition Corp I","BK4585":"ETF&股票定投概念","BK4592":"伊斯兰概念","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4588":"碎股","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4087":"商业印刷","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","CHMP":"冠军工业","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","BK4539":"次新股","BK4504":"桥水持仓","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4581":"高盛持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD"},"translate_title":"不受衰退影响的财富：在任何经济中都能茁壮成长的三只股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THAC":1,"AMAM":1,"SBUX":1,"PACI.U":1,"CHMP":1,"JNJ":1},"content_text":"These companies have the fundamental ability to capitalize on market leads and derive constant growth despite economic fluctuations.\nStarbucks (SBUX): The company recorded a solid increase in U.S. Rewards membership and billions loaded onto US Starbucks cards.\nGoldman Sachs (GS): The firm achieved a double-digit asset and wealth management net revenue boost.\nJohnson & Johnson (JNJ): The pharmaceutical segment delivered competitive global sales growth.\n\n\n\n\n\n \n\nSource: bangoland / Shutterstock\n\n\n\nFinding reliable assets is crucial in the current unstable environment. Even amid economic uncertainty, certain equities hold their value and offer steady returns. Three such luminaries are well-known in their fields. These three firms stand out as beacons of stability in the face of market turbulence: the first one with its strong loyalty program and worldwide development initiatives; the second with its consistent growth in wealth management; and the third with its inventive competence in medicines.\nTheir most recent results reveal that these companies survive and prosper throughout economic downturns, providing investors with a safe harbor for consistent growth. These companies are not just stable; they are also innovative. Their durability and flexibility make them appealing investments even in difficult times. \nWhether it’s the first company’s strong loyalty program and worldwide development initiatives, the second company’s fee-based revenue growth, or the third company’s groundbreaking cancer advances, their strategies are worth exploring. Discover the tactics and achievements that underpin these three stability pillars against market downturns.\nStarbucks (SBUX)\nSource: Grand Warszawski / Shutterstock.comIn Q1 2024, Starbucks (NASDAQ:SBUX) had 34.3 million active US Rewards members, a 13% growth from Q1 2023. The increase in membership shows how well Starbucks’ loyalty program encourages consumer interaction and return business. Moreover, the $3.6 billion placed into Starbucks cards in the US highlights the high level of consumer loyalty even further. This significant prepaid sum shows a high degree of client loyalty and gives Starbucks a reliable source of income.\nAdditionally, at the end of the first quarter, Starbucks had 38,587 locations worldwide, adding 549 net new locations. This rapid expansion shows the company’s capacity to break into new areas and satisfy unmet customer demand. Starbucks intentionally concentrates on two important countries to spur expansion, with 61% of its outlets in China and the United States combined. \nFurthermore, Starbucks’ international sector had a 10% growth in net revenues in Q1, despite obstacles including currency headwinds. This expansion demonstrates the company’s robust worldwide reach and capacity to seize various market possibilities. In short, Starbucks is still optimistic about its expansion in China, concentrating on gaining market share in the premium sector. \nGoldman Sachs (GS)\nSource: rafapress / Shutterstock.comGoldman Sachs (NYSE:GS) recorded a double-digit percentage boost in asset and wealth management revenues. The expanded management, other fees, and solid private banking and lending performance fueled the growth, indicative of Goldman Sachs’ consistent expansion in the segment.\nThe Asset & Wealth Management division delivered an 18% uplift in net sales from Q1 2023 to $3.79 billion in Q1 2024. Indeed, this expansion derived from the company’s capacity to draw in and hold onto customer assets. This boosts the fee-based top and bottom lines.\nFurthermore, the 32% increase in investment banking fees from 2022 emphasizes Goldman Sachs’ capacity to hike fee revenue from advisory services and debt and equity underwriting. This expansion shows how well the company executes high-value deals even under the adverse business environment.\nLastly, the Global Banking & Markets business recorded net sales of $9.73 billion for Q1 2024, up 15% from Q1 2023 and a solid 53% from the previous quarter. To sum up, the Global Banking & Markets division is seeing strong business activity. Hence, this reflects the double-digit percentage rise in net revenues compared to the same quarter last year and the previous year.  \nJohnson & Johnson (JNJ)\nSource: Alexander Tolstykh / Shutterstock.comThe Innovative Medicine sector of Johnson & Johnson’s (NYSE:JNJ) sales hit $13.6 billion, up 2.5% worldwide. Interestingly, US sales grew by a robust 8.4%. Johnson & Johnson’s pharmaceutical division’s robust performance reflects this trend, especially in its largest US market. The company’s unique pharmaceutical products are in consistent demand, as seen by the moderate rise in global sales.\nFurthermore, the company’s excellent expansion in oncology was fueled by the adoption of new products and major brands. For example, DARZALEX had a 21% rise, primarily due to improvements in share across all therapeutic lines. Additionally, vital clinical and regulatory milestones were reached, particularly in the field of cancer, whereby several medicines received positive Committee for Medicinal Products for Human Use (CHMP) views and US Food and Drug Administration authorization.\nThese pipeline benchmarks demonstrate how Johnson & Johnson’s pipeline progresses. The company is focused on creating novel solutions for unmet medical needs. Therefore, the purchase of Ambrx (NASDAQ:AMAM) highlights the company’s strategic commitment to growing in this therapeutic area and expanding its offering in cancer.\nAs of this writing, Yiannis Zourmpanos held a long position in JNJ. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nYiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.Bank, Consumer Discretionary, Financial, HealthcareBlue-Chip Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/04/recession-proof-riches-3-stocks-that-thrive-in-any-economy/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428119435"}